Ah I see davisite. However, you would also know that statistics...

Ah I see davisite. However, you would also know that statistics require power and although it was not ideal that the second experiment wasn’t statistically significant, there is power in the numbers. Despite larger numbers in expt 2 the combination is still significant which means the second expt probably only just missed significance. The fact there was an immune response in the T cell assay and the therapeutic assay showed promise, I don’t think they have lied in their announcement. They seems to have been quite honest actually which makes me think this is a company you can trust. I do think the results seem encouraging but there’s a long way to go to prove anything substantial. I think they have been reasonable in their announcement and haven’t tried to overinterpret the data. They are just looking at the positive aspects. I think you would want that in a company. I definitely wouldn’t want them to be pessimistic, they would never explore anything. I think you’re being rather hard on them. I continue to hold and if I had more money would be buying at these prices. Their core business is diagnostics and the next big announcement is the assay platform. I’m not talking this company but at the same time I do r like people who purposefully downramp either.